NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) finished Thursday with an addition of $0.02 to close at $0.62, an upside of 3.42 percent. An average of 541,874 shares of common stock have been traded in the last five days. There was a gain of $0.0855 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 496,878 shares traded, while the 50-day average volume stands at 458,469.
NRBO stock has increased by 38.39% in the last month. The company shares reached their 1-month lowest point of $0.4300 on 07/17/23. With the stock rallying to its 52-week high on 04/17/23, shares of the company touched a low of $0.36 and a high of $63.85 in 52 weeks. It has reached a new high 5 times so far this year and lost -13.59% or -$0.0823 in price. In spite of this, the price is down -99.03% from the 52-week high.
Valuation Metrics
NeuroBo Pharmaceuticals Inc. (NRBO) stock’s beta is -0.04. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.83.
Financial Health
The quick ratio of NeuroBo Pharmaceuticals Inc. for the three months ended June 29 was 2.90, and the current ratio was 2.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, NeuroBo Pharmaceuticals Inc.’s return on assets was -66.30%.
Earnings Surprise
The company posted a net income of -$0.73 million in the quarter, while revenues of -$2.6 million were shrunk -352.05%. The analyst consensus anticipated NeuroBo Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.13 per share, but it turned out to be -$0.02, a 84.60% surprise. At the end of the quarter ending June 29, NeuroBo Pharmaceuticals Inc.’s stock balance sheet showed total liabilities of 3.98 million. Shareholders own equity worth $38.43 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at NeuroBo Pharmaceuticals Inc. (NRBO) price momentum. RSI 9-day as of the close on 10 August was 70.75%, suggesting the stock is Overbought, with historical volatility in this time frame at 115.51%.
As of today, NRBO’s price is $0.5631 +15.55% or $0.0855 from its 5-day moving average. NRBO is currently trading +45.52% higher than its 20-day SMA and -3.76% lower than its 100-day SMA. However, the stock’s current price level is +13.98% above the SMA50 and -93.11% below the SMA200.
The stochastic %K and %D were 65.00% and 46.41%, respectively, and the average true range (ATR) was 0.0537. With the 14-day stochastic at 92.59% and the average true range at 0.0505, the RSI (14) stands at 65.62%. The stock has reached 0.0407 on the 9-day MACD Oscillator while the 14-day reading was at 0.0476.
Analyst Ratings
H.C. Wainwright launched coverage on NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) in its analyst report released on June 15, 2020. The firm assigned the stock a Buy rating. The consensus rating for NeuroBo Pharmaceuticals Inc. (NRBO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NRBO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is NRBO’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $6.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for NeuroBo Pharmaceuticals Inc. (NRBO) stock is $6.00.
